Navigation Links
Gleevec Prevents Return of Intestinal Cancer, Study Confirms
Date:3/19/2009

Drug is shown to be most effective on larger tumors

THURSDAY, March 19 (HealthDay News) -- Taking Gleevec after surgery to remove a gastrointestinal stromal tumor improves tumor-free survival, a U.S. study has confirmed.

Gastrointestinal stromal tumors (GIST), the most common soft-tissue cancer of the intestinal tract, typically occur in the stomach or small intestine. About 3,000 to 4,000 cases are diagnosed in the United States each year. According to background information in the study, about 85 percent of these tumors have a protein that allows them to be inhibited by Gleevec, known as imatinib.

The finding stems from a phase 3 trial for the drug, which was approved last year by the U.S. Food and Drug Administration to treat people who've had surgery to remove a GIST. The drug already was approved for treating certain types of adult leukemia.

The trial included more than 700 people with a GIST at least 3 centimeters in size that tested positive for the protein. The participants were randomly selected to take either 400 milligrams of Gleevec or a placebo once a day for a year after surgery to remove their tumor.

After a median follow-up of almost 20 months, 8 percent of people in the Gleevec group and 20 percent of those in the placebo group had experienced tumor recurrence or had died. After a year, recurrence-free survival was 98 percent for those taking the drug and 83 percent for people taking the placebo.

Tumor size affected treatment success, the study found. Gleevec had the most effect on tumors that were 10 cm or larger, less effect on tumors between 6 and 10 cm, and the least effect on tumors between 3 and 6 cm, the study reported.

The most common serious side effects experienced by people taking the drug were dermatitis, abdominal pain and diarrhea.

Dr. Ronald DeMatteo, of Memorial Sloan-Kettering Cancer Center, and his fellow researchers said that their "findings will affect the management of patients with primary gastrointestinal stromal tumor and could have relevance to the adjuvant use of other molecular agents for cancer."

The study appears online and in an upcoming print issue of The Lancet.

Dr. Peter Hohenberger, of the University of Heidelberg, in Mannheim, Germany, said in an accompanying comment that more research is needed.

"There are so many unknowns that this trial might not be able to provide a definitive treatment decision," he wrote. "To refine the indication for adjuvant treatment remains the big task for future studies."

More information

The American Cancer Society has more about GIST.



-- Robert Preidt



SOURCE: The Lancet, news release, March 18, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports
2. Prescription Copay Assistance for Patients taking Gleevec or Tasigna for Philadelphia chromosome-positive Chronic Myelogenous Leukemia (Ph+ CML)
3. Cancer Drug Gleevec Could Fight Stroke
4. Cancer Drug Gleevec Linked to Muscle Damage
5. Protein predicts Gleevec resistance in gastrointestinal tumors
6. Gleevec Pushes Advanced Melanoma Into Remission
7. Gleevec May Disrupt Ovarian Function
8. Photo: New Data Show Gleevec(R) Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
9. Gleevec, the targeted cancer pill, delivers more good news to patients
10. Cell pathway on overdrive prevents cancer response to dietary restriction
11. New surgical implant tested at U-Iowa prevents total blindness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gleevec Prevents Return of Intestinal Cancer, Study Confirms
(Date:6/23/2017)... ... June 23, 2017 , ... Jusino Insurance ... to communities in the greater Chicago metropolitan area, is embarking on a charity ... youth in Chicago. , Founded in 1897, Hephzibah Children’s Association is one of ...
(Date:6/22/2017)... CA (PRWEB) , ... June 22, 2017 , ... Plastic ... named as a Top Doctor for 2017. Each year, research and information firm, Castle ... First winning the title in 2015, this marks the 3rd time that Dr. ...
(Date:6/22/2017)... ... June 22, 2017 , ... The VA Maryland Health ... Network has awarded the Baltimore VA Medical Center, a division of the VA ... its efforts to promote waste reduction and promote recycling. Also, Practice Greenhealth ...
(Date:6/20/2017)... ... June 20, 2017 , ... Connance, a leading ... will present how predictive analytics drive reimbursement optimization, with a focus on denial ... 25-28. , “The traditional approach to denied and underpaid claims leaves money ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Fresenius Vascular Care, ... minimally invasive techniques to treat and manage a wide range of vascular conditions, has ... initiative. With more than 65 centers represented by more than 40 local brands, a ...
Breaking Medicine News(10 mins):
(Date:6/11/2017)... 10, 2017  Eli Lilly and Company (NYSE: ... 3 studies of galcanezumab, an investigational treatment for the ... on several key secondary endpoints for galcanezumab compared to ... studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today ... in Boston . ...
(Date:6/8/2017)...   Responding to Heath Ledger,s father,s recent ... singer Chris Cornell in May, the mental health ... free online psychiatric drug side effects search ... psychotropic drug risks. The father of the ... accidental overdose, has called for tighter rules on prescription drugs. ...
(Date:6/5/2017)... 2017 The Cincinnati location ... Inc. (NYSE: DPLO), has been awarded a Top Workplaces ... Results are based on an employee survey administered by ... workplace improvement. The survey measures several aspects of workplace culture, ... ...
Breaking Medicine Technology: